Jazz Pharmaceuticals PLC
(NAS:JAZZ)
$
121.59
-1.05 (-0.86%)
Market Cap: 7.35 Bil
Enterprise Value: 10.93 Bil
PE Ratio: 17.13
PB Ratio: 1.76
GF Score: 85/100 Jazz Pharmaceuticals PLC at Jefferies Healthcare Conference (Virtual) Transcript
Jun 03, 2020 / 08:30PM GMT
Release Date Price:
$118.74
(+0.74%)
David Michael Steinberg
Jefferies LLC, Research Division - Specialty Pharma Analyst & Equity Analyst
Good afternoon, everyone, and welcome to the Jefferies Healthcare Conference. I'm Dave Steinberg, Specialty Pharma Analyst at Jefferies. And we're delighted to have with us the management team of Jazz. With us today is Bruce Cozadd, long time CEO and one of the founders and Chairman. So Bruce, good afternoon and welcome.
Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO
David, good to be with you.
Questions & Answers
David Michael Steinberg
Jefferies LLC, Research Division - Specialty Pharma Analyst & Equity Analyst
So let's start with Xyrem. We'll start right at the top. So Xyrem outperformed in 2019, and it was tracking to do so in the first quarter until March -- mid-March when COVID hit, unfortunately. And on the Q1 call, you lowered guidance due to the impact COVID was having on your business in April.
So a couple of questions, Bruce. What are you seeing in
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot